Fran Curtis is a five-time survivor of cancers survivor including breast, appendix and skin cancer, but she told CURE in a ...

The potential of moving the combination to the earlier MIBC setting significantly increases the Padcev market.

The first iteration of HER2-targeted drugs showed limited activity in bladder cancer, but the rise of antibody-drug ...

Beijing Time (09:00 am Berlin Time) on October 20, the 'Global Launch Event for Iza-bren (EGFR×HER3 Bispecific ADC) Nasopharyngeal Carcinoma BL-B01D1-303 Research Results' was held at the venue of the ...

Data from NIAGARA supported the FDA’s approval of neoadjuvant durvalumab in combination with gemcitabine and cisplatin, ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

KEYTRUDA is indicated for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then ...

A New Era in the Treatment of Muscle Invasive Bladder Cancer. Discussant of LBA2 - Perioperative (Periop) Enfortumab Vedotin ...

HER-2 targeted antibody-drug conjugate monotherapy has demonstrated efficacy in the post-chemotherapy setting for ...

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. We're maintaining the criteria we used for last year's ...